Publications by authors named "Tie-Nan Zhou"
Article Synopsis
- * Researchers compared two groups: those receiving antithrombotic drugs (208 patients) and those not receiving them (489 patients), considering outcomes like early mortality and aortic-related events over 1 month and 18 months.
- * Results showed no significant differences between the two groups in terms of mortality and aortic events, suggesting that antithrombotic treatment doesn’t impact these outcomes in either the early or late term after treatment.
Backgrounds: Survival and aortic-related adverse events after thoracic endovascular aortic repair (TEVAR) for aortic intramural hematoma (IMH) and aortic dissection (AD) are controversial. We aimed to assess the preoperative characteristics and to evaluate TEVAR outcomes of acute type B IMH and AD.
Methods: Between June 2002 and May 2021, 83 patients with acute type B IMH and 755 patients with acute type B AD underwent TEVAR at the General Hospital of Northern Theater Command.
Background: In clinical practice, some cases indicated that the loading dose of bivalirudin increased the bleeding risk, particularly in patients with renal insufficiency. Therefore, this study aimed to assess the efficacy and safety of the low-dose (80%) bolus injection of bivalirudin in patients undergoing cardiac catheterization stratified by renal function.
Methods: A total of 204 individuals in the REDUCE BOLUS trial were stratified 1:1 to the estimated glomerular filtration rate (eGFR) ≥ 60 ml/min cohort or eGFR < 60 ml/min cohort, then randomized 1:1 to the reduced bolus bivalirudin group (i.
Background: The dose and time point for switching from clopidogrel to ticagrelor remain controversial, especially for Chinese acute coronary syndrome (ACS) patients with complicated coronary artery disease (CAD). Hence, the purpose of this study was to further explore the optimal dose and time point for the switching strategy to balance the increase in platelet inhibition and the decrease in adverse events in Chinese ACS patients with complicated CAD managed by percutaneous coronary intervention (PCI).
Methods: From July 2017 to December 2017, the prospective, randomized, open-label study (the SwitcHIng from clopidogrel to ticagrelor study) assigned the eligible Chinese ACS patients with complicated CAD managed by PCI (n = 102) for 90 mg of ticagrelor at 12 h (T-90 mg-12 h), 90 mg of ticagrelor at 24 h (T-90 mg-24h) or 180 mg ticagrelor at 24 h (T-180 mg-24 h) after the last dose of clopidogrel.
Background: Females with ST-segment elevation myocardial infarction (STEMI) have higher in-hospital and short-term mortality rates compared with males in China, suggesting that a sex disparity exists. The age of onset of STEMI is ahead of time and tends to be younger. However, there are relatively little data on the significance of sex on prognosis for long-term outcomes for adult patients with STEMI after percutaneous coronary intervention (PCI) in China.
View Article and Find Full Text PDFArticle Synopsis
- Acute aortic dissection is a serious condition, and this study aimed to assess the role of antiplatelet therapy (specifically aspirin) in patients with Stanford Type B aortic dissection who had endovascular aortic repair (EVAR).
- The study analyzed data from 388 patients, revealing that a significant portion received aspirin treatment; however, those who did were generally older and had more comorbidities like hypertension and diabetes.
- Results showed similar rates of complications like death, hemorrhage, and recurrent dissection between the aspirin and no-aspirin groups, suggesting that aspirin may not significantly impact outcomes for these patients within the first year.
Objective: To elucidate the effects of dual antiplatelet therapy on platelet response in acute myocardial infarction patients with chronic kidney disease.
Methods: From September 2011 to June 2012, a total of 195 acute myocardial infarction patients with drug eluting stent implanting were enrolled. Among them, 133 cases had normal renal function and 62 cases suffered chronic kidney disease (CKD).